Intra-Cellular Therapies, Inc.

Form 3

September 09, 2013

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

**SECURITIES** 

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

À LERNER RICHARD A

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

08/29/2013

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

Intra-Cellular Therapies, Inc. [NONE]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

C/O INTRA-CELLULAR THERAPIES, INC., 3960 **BROADWAY** 

(Street)

10% Owner \_X\_ Director Officer Other (give title below) (specify below)

(Check all applicable)

6. Individual or Joint/Group Filing(Check Applicable Line)

\_X\_ Form filed by One Reporting Person

Form filed by More than One

Reporting Person

NEW YORK. NYÂ 10032

(City) (State)

1. Title of Security (Instr. 4)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

2. Amount of Securities Beneficially Owned

(Instr. 4)

3. Ownership Form:

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Direct (D) or Indirect (I)

(Instr. 5)

Common Stock 37,500 Ι

Held by the Lerner Family Trust UAD 11/14/94 (1)

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying

Conversion

6. Nature of Indirect Ownership Beneficial Ownership

**Derivative Security** or Exercise Form of (Instr. 5)

Edgar Filing: Intra-Cellular Therapies, Inc. - Form 3

	Date Exercisable	Expiration Date	(Instr. 4)		Price of	Derivative	
			Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (right to buy)	(2)	12/05/2016	Common Stock	10,000	\$ 1.36	D	Â
Stock Option (right to buy)	(2)	12/12/2017	Common Stock	12,500	\$ 1.5	D	Â
Stock Option (right to buy)	(2)	12/18/2018	Common Stock	12,500	\$ 1.5	D	Â
Stock Option (right to buy)	(2)	06/10/2020	Common Stock	12,500	\$ 2.74	D	Â
Stock Option (right to buy)	(2)	12/21/2020	Common Stock	12,500	\$ 2.74	D	Â
Stock Option (right to buy)	(2)	04/30/2022	Common Stock	12,500	\$ 2.84	D	Â
Stock Option (right to buy)	(3)	05/30/2023	Common Stock	12,500	\$ 3.26	D	Â
Stock Option (right to buy)	(4)	05/30/2023	Common Stock	20,000	\$ 3.26	D	Â

# **Reporting Owners**

Reporting Owner Name / Address	Relationships				
<b></b>	Director	10% Owner	Officer	Other	
LERNER RICHARD A C/O INTRA-CELLULAR THERAPIES, INC. 3960 BROADWAY NEW YORK, NY 10032	ÂX	Â	Â	Â	

## **Signatures**

/s/ Lawrence J. Hineline, Attorney-in-fact 09/09/2013

\*\*Signature of Reporting Person Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Dr. Lerner may be deemed to beneficially own securities held by the Lerner Family Trust UAD 11/14/94 (the "Lerner Family Trust"). Dr. Lerner disclaims beneficial ownership of securities held by the Lerner Family Trust except to the extent of his pecuniary interest therein.
- (2) All shares underlying this option have vested.
- (3) The option vests as to 50% of the shares on July 1, 2013 and 50% of the shares on July 1, 2014.
- (4) The option vests as to 50% of the shares on July 1, 2014 and 50% of the shares on July 1, 2015.

Reporting Owners 2

#### Edgar Filing: Intra-Cellular Therapies, Inc. - Form 3

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.